Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Authors

Frederick L. Locke, Moffitt Cancer Center
Armin Ghobadi, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

2020

Volume

4

Issue

19

First Page

4898

Last Page

4911

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2020002394

Rights and Permissions

Frederick L. Locke, John M. Rossi, Sattva S. Neelapu, Caron A. Jacobson, David B. Miklos, Armin Ghobadi, Olalekan O. Oluwole, Patrick M. Reagan, Lazaros J. Lekakis, Yi Lin, Marika Sherman, Marc Better, William Y. Go, Jeffrey S. Wiezorek, Allen Xue, Adrian Bot; Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 2020; 4 (19): 4898–4911. doi: https://doi.org/10.1182/bloodadvances.2020002394

Recommended Citation

Locke, Frederick L.; Ghobadi, Armin; and al., et, "Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma." Blood Advances. 4, 19. 4898 - 4911. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9734